Advanced Biomed (ADVB) Common Equity (2023 - 2026)

Advanced Biomed has disclosed Common Equity across 4 years of filings, most recently posting $9.2 million for Q1 2026.

• Common Equity for Q1 2026 came in at $9.2 million, up 123.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.2 million (up 123.01% YoY), and the FY2025 annual result was $3.5 million, up 109.08% from the prior year.
• Common Equity came in at $9.2 million for Q1 2026 at Advanced Biomed, down from $9.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $9.5 million in Q4 2025 to a low of -$497797.0 in Q1 2024.
• The 4-year median for Common Equity is $2.3 million (2024), against an average of $3.2 million.
• Peak annual rise in Common Equity reached 1431.69% in 2025, while the deepest fall reached 109.08% in 2025.
• Advanced Biomed's Common Equity stood at $196841.0 in 2023, then surged by 214.48% to $619032.0 in 2024, then surged by 1431.69% to $9.5 million in 2025, then fell by 2.87% to $9.2 million in 2026.
• The last three Common Equity figures came in at $9.2 million (Q1 2026), $9.5 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.